DANVERS, MA, USA, 2025 年 4 月 8 日 - Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, and Visiopharm, a global leader in AI-driven precision pathology software, today announced a strategic partnership to advance spatial biology research. The collaboration enables more streamlined analysis of images generated using the SignalStar® Multiplex IHC technology in Visiopharm's Phenoplex software, helping researchers to more efficiently interrogate cellular interactions in the tumor microenvironment and streamline biomarker discovery and analysis.
“As multiplexed spatial biology assays become more flexible and robust, they must be paired with powerful, AI-driven image analysis solutions to truly uncover meaningful insights,” says Roberto (Roby) Polakiewicz, PhD, Chief Scientific Officer at CST. “We’re excited to partner with Visiopharm to provide researchers with a comprehensive toolbox of proven solutions so they can conduct advanced analyses of the tumor microenvironment with confidence.”
Through the partnership, CST and Visiopharm will deliver multiplexed biomarker staining, signal amplification, and data annotation and analysis capabilities, enabling spatial biology researchers to uncover actionable insights about disease progression and therapeutic response.
“At Visiopharm, we are committed to empowering researchers with AI-driven image analysis solutions that unlock the full potential of spatial biology,” said Regan Baird, PhD, Senior Vice President, Commercial Strategy Deployment at Visiopharm. “By combining CST’s cutting-edge multiplex IHC technology with our advanced Phenoplex software, we are enabling scientists to extract deeper, more precise insights into the tumor microenvironment. This partnership represents a significant step forward in accelerating biomarker discovery and advancing precision medicine.”
Visiopharm is a world leader in AI-based image analysis and workflow standardization, and CST offers best-in-class antibody technology for interrogating complex biological systems while maintaining their spatial context and tissue architecture. By combining the highly flexible antibody panels in the SignalStar Multiplex IHC assay with powerful AI-driven software from Visiopharm, biopharma researchers can confidently generate and analyze spatial data of the tumor microenvironment using a high-throughput method.
To demonstrate how CST and Visopharm’s capabilities in multiplex immuno-profiling can be leveraged together, the companies are presenting a poster at The American Association for Cancer Research (AACR) Annual Meeting 2025.
To learn more, visit CST at AACR 2025 at booth #809 or stop by poster number 24 in the “Spatial Proteomics and Transcriptomics 1” poster session.
Cell Signaling Technology（CST）是一家与众不同的生命科学公司，由活跃在科研一线的科学家创立、拥有并经营，秉承高标准的产品与服务质量、技术创新和科学严谨性。于 1999 年创立，总部位于美国马萨诸塞州丹弗斯，全球有 600 多名员工。我们始终如一地为全球的科学家提供高质量产品与服务，助力他们对科学发现的探求。CST坚持以人为本，以科学为本——是一家坚持服务客户，帮助社区，关爱地球的公司。如需了解更多信息，请访问 CST 中国官网：cellsignal.com
Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company's headquarters are located in Denmark's Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
CST Media and Press
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
全球营销传播高级总监
Phone: +1-978-880-3334
电子邮件：[电子邮件受保护]